Medical devices, healthcare technology and the business of care
PMA approval · P170011

Impella RP System

Abiomed, Inc. · Decision date Sep 20, 2017

MEDTECHLEDGER EXPLANATIONP170011

What did the FDA approve?

FDA approved the Impella RP System under PMA P170011 on September 20, 2017. The approval covers a temporary non-roller type right heart support blood pump indicated for temporary right ventricular support for up to 14 days in patients with a body surface area of 1.5 m2 or greater who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.

The applicant is Abiomed, Inc., and the device is classified under product code PYX in the cardiovascular specialty. The source statement reports the approved indication and duration of support but does not include safety or effectiveness data, clinical trial results, or comparative performance information. No supplement type or supplement reason is recorded, so this entry reflects the original PMA approval rather than a change to a previously approved system.

FDA approval order statement

Approval for the Impella RP System. This device is indicated for providing temporary right ventricular support for up to 14 days in patients with a body surface area greater than or equal to 1.5 m2, who develop acute right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant, or open-heart surgery.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Sep 20, 2017

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P170011
Regulatory pathway
Premarket approval application
Applicant
Abiomed, Inc.
Product code
PYX
Decision code
APPR
Decision date
Sep 20, 2017
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Temporary non-roller type right heart support blood pump.

Applicant
Abiomed, Inc.
Product code
PYX
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P170011 received

    Application receipt date recorded by FDA.

  2. P170011 · FDA decision

    APPR

  3. P170011/S064 · Related supplement

    Impella RP Flex with SmartAssist

Timeline entries are records held by MedtechLedger for P170011. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170011

Product / regulatory recordCompanyPathwayDecision dateSource
Abiomed, Inc.PMA supplementOct 26, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Abiomed, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
22 Cherry Hill Dr., Danvers, MA, 01923

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records